Acumen Pharmaceuticals, Inc. (ABOS) Key Metrics
ABOS valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $122.2M
- Enterprise value
- $88.1M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 538.8
- Price / book
- 2.9 10-yr median 1.1
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 0.33
ABOS key metrics, 2019–2025
Fiscal year ended December 31, 2025 · U.S. dollarsABOS valuation Price multiples at each fiscal year-end price.
ABOS returns How much profit the business earns on the capital it uses.
ABOS per-share figures Results divided by the shares outstanding at year-end.
ABOS financial health Debt, liquidity and how easily interest is covered.
ABOS efficiency & capital use Working capital cycle and where the cash goes.
ABOS valuation history
ABOS returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
ABOS debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
ABOS cash returned to shareholders
ABOS price vs earnings per share
ABOS key metrics
2019–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Valuation | |||||||
| Market capitalization | $127.8M | $103.2M | $186.7M | $219.3M | $258.7M | — | — |
| Enterprise value | $42.2M | −$38.6M | −$28.4M | $41.8M | $64.6M | — | — |
| Price / sales | — | — | — | — | 180.1 | — | — |
| Price / book | 1.8 | 0.6 | 0.7 | 1.2 | 1.1 | — | — |
| EV / sales | — | — | — | — | 45.0 | — | — |
| Earnings yield | −95.0% | −99.1% | −28.1% | −19.5% | −38.9% | — | — |
| Free cash flow yield | −90.5% | −83.5% | −23.1% | −16.1% | −7.0% | — | — |
| Dividend yield | — | 0.0% | 0.0% | — | — | — | — |
| Shareholder yield (dividends + buybacks) | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Share price at fiscal year-end | $2.11 | $1.72 | $3.84 | $5.40 | $6.76 | — | — |
| Per share | |||||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.04 | $0.05 | $0.06 |
| Earnings per share | −$2.00 | −$1.71 | −$1.08 | −$1.06 | −$2.63 | −$0.26 | −$0.28 |
| Operating cash flow per share | −$1.91 | −$1.44 | −$0.89 | −$0.87 | −$0.47 | −$0.26 | −$0.24 |
| Free cash flow per share | −$1.91 | −$1.44 | −$0.89 | −$0.87 | −$0.47 | −$0.26 | −$0.24 |
| Cash per share | $1.93 | $2.86 | $5.01 | $4.37 | $5.08 | $1.53 | $0.23 |
| Book value per share | $1.16 | $3.03 | $5.49 | $4.65 | $5.88 | −$0.65 | −$0.40 |
| Tangible book value per share | $1.16 | $3.03 | $5.49 | $4.65 | $5.88 | −$0.65 | −$0.40 |
| Dividends per share | — | $0.00 | $0.00 | — | — | — | — |
| Capex per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Debt per share | $0.52 | $0.49 | $0.59 | $0.00 | $0.01 | — | — |
| Shares outstanding | 60.6M | 60.0M | 48.6M | 40.6M | 38.3M | 28.7M | 28.7M |
| Change in shares outstanding | +0.9% | +23.5% | +19.7% | +6.1% | +33.6% | 0.0% | — |
| Returns & profitability | |||||||
| Return on equity (ROE) | −96.2% | −45.6% | −23.0% | −20.7% | −97.4% | — | — |
| Return on invested capital (ROIC) | — | −196.0% | −152.8% | −168.5% | — | — | — |
| Return on assets (ROA) | −67.1% | −37.3% | −20.7% | −20.1% | −73.2% | −28.3% | −108.0% |
| Return on tangible assets | −98.8% | −42.8% | −16.9% | −21.8% | −43.7% | −16.5% | −108.0% |
| Free cash flow margin | — | — | — | — | — | −518.8% | −401.8% |
| Financial health | |||||||
| Total debt | $31.3M | $29.7M | $28.5M | $105,000 | $201,000 | — | — |
| Cash & short-term investments | $116.9M | $171.6M | $243.5M | $177.6M | $194.2M | $43.8M | $6.6M |
| Net debt | −$85.6M | −$141.9M | −$215.0M | −$177.5M | −$194.0M | −$43.8M | −$6.6M |
| Debt / equity | 0.44 | 0.16 | 0.11 | 0.00 | 0.00 | — | — |
| Debt / assets | 0.25 | 0.12 | 0.09 | 0.00 | 0.00 | — | — |
| Net debt / EBITDA | — | — | — | — | — | — | −55.06 |
| Current ratio | 4.07 | 6.46 | 19.01 | 23.08 | 38.60 | 6.98 | 5.35 |
| Quick ratio | 4.07 | 6.45 | 19.01 | 23.06 | 38.60 | 6.96 | 5.31 |
| Interest coverage | -29.3 | -28.0 | -105.2 | -19.0 | -0.2 | — | — |
| Working capital | $92.2M | $150.7M | $233.6M | $172.5M | $193.5M | $38.1M | $5.8M |
| Invested capital | −$15.1M | $40.0M | $51.9M | $11.3M | $31.1M | −$62.4M | −$18.0M |
| Tangible asset value | $70.4M | $181.7M | $266.8M | $188.8M | $225.2M | −$18.6M | −$11.4M |
| Net current asset value | $69.8M | $121.1M | $203.5M | $172.5M | $193.5M | −$18.6M | −$11.6M |
| Graham net-net per share | $1.07 | $1.91 | $4.13 | $4.18 | $4.94 | −$0.67 | −$0.42 |
| Capital allocation | |||||||
| Dividends paid | — | $0 | $0 | — | — | — | — |
| Share buybacks (net) | $73,000 | $41,000 | $0 | $0 | $0 | — | — |
| Capex / revenue | — | — | — | — | 2.8% | 2.8% | 2.4% |
| Capex / depreciation | 0.48 | 0.09 | 0.11 | 0.95 | 10.00 | 10.00 | 10.00 |
| Stock-based compensation / revenue | — | — | — | — | 64.2% | 10.7% | 10.3% |
| R&D / revenue | — | — | — | — | 856.9% | 556.9% | 505.4% |
| SG&A / revenue | — | — | — | — | 506.9% | 94.1% | 54.6% |
| Efficiency | |||||||
| Days sales outstanding | — | — | — | — | 13.8 | 17.7 | 6.5 |
| Days of inventory on hand | — | 263.5 | 1.3 | 215.0 | 1.4 | 3.2 | 2.1 |
| Days payables outstanding | 6,151.4 | 7,204.6 | 13.0 | 2,945.9 | 24.0 | 17.2 | 9.5 |
| Cash conversion cycle (days) | — | — | — | — | -8.8 | 3.7 | -1.0 |
| Receivables turnover | 0.00 | 0.00 | 0.00 | — | 26.37 | 20.66 | 56.57 |
| Payables turnover | 0.06 | 0.05 | 28.03 | 0.12 | 15.20 | 21.21 | 38.46 |
| Inventory turnover | — | 1.39 | 284.97 | 1.70 | 270.19 | 114.24 | 175.02 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.06 | 0.23 |
| Average receivables | $511,500 | $311,500 | $112,400 | −$141 | $54,458 | $69,500 | $30,000 |
| Average payables | $3.1M | $3.5M | $1.5M | $1.4M | $809,500 | $377,000 | $223,000 |
| Average inventory | — | $128,500 | $148,500 | $99,542 | $45,542 | $70,000 | $49,000 |
| Intangibles / total assets | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from ABOS's annual financial statements (latest annual report filed March 26, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
ABOS valuation and financial ratios
Acumen Pharmaceuticals earned a return on equity of −96.2% in fiscal 2025. It ended the year with $31.3 million of debt and $116.9 million in cash and short-term investments, a net cash position of $85.6 million. It returned $0.1 million to shareholders: $0 in dividends and $0.1 million in share buybacks. The share count rose 111.4% from 28.7M to 60.6M over 6 years.
See the ABOS income statement, the ABOS chart for price history, or the ABOS stock overview for the latest quote and news.
ABOS key metrics FAQ
What is Acumen Pharmaceuticals's return on equity?
Acumen Pharmaceuticals's return on equity (ROE) was −96.2% in fiscal 2025: net income of -$121.3 million on average shareholders' equity of $126.1 million.
How much debt does Acumen Pharmaceuticals have?
Acumen Pharmaceuticals had total debt of $31.3 million at the end of fiscal 2025, a debt-to-equity ratio of 0.44 and more cash than debt.
Does Acumen Pharmaceuticals buy back its shares?
Yes. Acumen Pharmaceuticals spent $0.1 million on net share repurchases in fiscal 2025 Shares outstanding changed +0.9% over the year, to 60.6M..
What is Acumen Pharmaceuticals's free cash flow yield?
Acumen Pharmaceuticals generated -$115.6 million of free cash flow in fiscal 2025, a free cash flow yield of −90.5% on its market value at year-end ($127.8 million).
What is Acumen Pharmaceuticals's current ratio?
Acumen Pharmaceuticals's current ratio was 4.07 at the end of fiscal 2025: current assets were 4.07 times current liabilities.